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Quality assurance and quality control have become important aspects of transfusion medicine. Licensing and accreditation of blood transfusion laboratories and centres is gaining importance. In some countries, quality assurance and control are compulsory, and accreditation of blood transfusion services is required. It seemed of interest to obtain information on the present situation concerning this aspect of transfusion medicine in various countries as well as on the systems on which quality assurance and control are based. To obtain such information, the questions outlined below were sent to 27 experts in the field, in 24 countries, and answers were obtained from 22 of them, covering 18 countries. We give a survey of the information obtained but the reader is advised to examine the individual answers in order to fully appreciate the developments in this field.
Questions
(1) Is there an obligatory or voluntary, organized form of quality assurance in your country?
If so, on which system is it based? (GMP, GLP, GCP, ISO 9000 series, EN 45001, FDA, AABB, Council of Europe: Guide to the preparation and quality assurance of blood components) or other.
(2) If there is a systematic control of your quality system, who or which body/bodies is/ are responsible? (3) If there is no quality assurance system in your country (obligatory or voluntary), is such a system envisaged in the near future?
If so, on which system will it be based (see question 1)? (4) Is accreditation of blood transfusion laboratories/centres required or advocated in your country? If so, by whom or which body and on which system will it be based (1)?
Which body is responsible for granting or refusing accreditation?
What are the consequences if accreditation is refused? (5) Is your centre accredited or are there centres in your country which are accredited? And if so, since when?
Comments
Question 1. It is clear that in virtually all countries from which a contribution was received, quality assurance and control are obligatory for all or some aspects of blood transfusion. In all countries but one, quality assurance of blood products and their preparation is mandatory. It is, nearly everywhere, based on GMP and, in many countries, also on the 'Guidelines to the preparation, use and quality assurance of blood components' of the Council of Europe (1999) .
In many countries, quality assurance of blood transfusion services is also compulsory, although it is still voluntary in some. It is based on the ISO 9000 series, the Council of Europe guidelines or both, or on EN 45001, which will be replaced by ISO/IEC 17025 (all three in one country) and in the USA on the FDA guidelines for blood transfusion laboratories/centres. For a survey, see table 1.
Question 2. In nearly all countries where quality assurance is compulsory, the ultimate responsibility rests with the government. However, often the practical aspects of quality assurance are delegated to other bodies, e.g. the National Blood Transfusion Service, the Red Cross and even to a foreign institution (Hong Kong, see Lin).
Question 3. Because there is obligatory quality assurance in nearly all countries from which a contribution was received, there were only two direct answers to this question. In Italy (see Mozzi et al.) , new national and regional laws on blood transfusion are under discussion and include accreditation and thus quality assurance of blood transfusion services. In Sweden (Åkerblom and Messeter), although there are two quality assurance systems for blood centres, a discussion has started on creating a new 'Swedish Quality System for Blood Services' based on GMP, the new ISO 17025 (which replaces EN 45001) and including relevant elements from the new ISO 9001 series.
Question 4. Accreditation, certification or a license are required in most countries and are under discussion in others. In three countries accreditation is required for the preparation of blood products but not for blood transfusion laboratories (Czech Re-Vox Sang 2000;79: [253] [254] [255] [256] [257] [258] [259] [260] [261] [262] [263] [264] International Forum public, Sweden and the UK). Mostly again, the ultimate responsibility rests with the government. Refusal of accreditation may lead to severe measures and ultimately to closure of the unit. Question 5. In some countries there are blood transfusion centres that have been or are in the process of being officially accredited. To obtain a full picture of the present situation, the reader is advised to read the answers to questions 4 and 5.
In conclusion, it is clear that quality assurance and control have become an integral part of blood transfusion. In nearly all countries, official, obligatory quality assurance systems are in force, mostly for both blood products and their preparation as well as the laboratory procedures connected with blood transfusion. In the few countries where there is, as yet, no obligatory quality assurance, its institution is under discussion. Accreditation, certification of, or a license for transfusion laboratories is required in several countries or is being discussed. Quality assurance systems for blood products are based on GMP and the Council of Europe 'Guide to the preparation, use and quality control of blood components', and on the ISO 9000 series, GLP, the Council of Europe guidelines and the EN 45001 series, which will be replaced by ISO/IEC 17025 and in the USA on the FDA guidelines for blood transfusion laboratories/centres for the quality assurance of laboratories and centres. 
Peter Flanagan
In New Zealand, blood and blood products that are intended for therapeutic use are defined as medicines and are therefore subject to the requirements of the Medicines Act 1981, the Medicines regulations 1984 and subsequent amendments. These specific statutory requirements define the environment in which quality systems for the assurance of safe blood and blood products have been developed.
New Zealand Blood Service (NZBS) was established in July 1998 as the sole provider of blood and blood products within New Zealand. A national quality system is being established that will conform to the requirements of both GMP and ISO 9000. The desirability of moving to formal ISO certification remains under review.
Blood centres within the country are required to be licensed by Medsafe, the regulatory arm of the Ministry of Health. This requirement has been in place since approxi-mately 1993. Licenses to manufacture are issued on an annual basis following formal audit inspections. These external quality audits are undertaken against two main standards.
(1) The New Zealand Code of Good Manufacturing Practice for Manufacture and Distribution of Therapeutic Goods part 2: manufacture of blood and blood products. This document is based on the Australian Code with some minor modifications. Utilising a GMP based approach it identifies the key elements of an effective quality system. It also includes technical standards.
(2) The New Zealand Minimum Standards for the Collection, Processing and Quality Assurance of Blood and Medicines derived from Human Plasma. This document initially produced in 1996 provides comprehensive technical standards. The Ministry of Health initially produced the Minimum Standards. In 1998, following its establishment as the single national entity for the supply of blood and blood products, responsibility passed to NZBS. Formal systems for change control have been agreed with Medsafe. The Council of Europe 'Guide to the Preparation and Quality Assurance of Blood Components' is utilised as an external standard for the review process.
NZBS is responsible for provision of blood services from 'vein to vein'. This involves responsibility for hospital-based blood transfusion in addition to the manufacturing role. NZBS directly manages the larger blood banks. The smaller blood banks are operated by the local hospital under a contract with NZBS. The contract defines the requirements and standards that the blood bank must maintain. One specific requirement is that the laboratory is accredited by International Accreditation New Zealand (IANZ). IANZ is an external independent organisation that audits against the New Zealand Code of Laboratory Management Practice (NZCLMP).
The blood transfusion sector in New Zealand is highly regulated with requirements for accreditation of both the manufacturing and blood banking sector. The expectations of the accreditation authorities continue to increase. At this stage, however, there is no instance where a blood centre or blood bank has been refused accreditation. Dr Bjarte G. Solheim
Questions 1 and 2
In Norway, both cellular and plasma blood products are defined as medicinal products and are thus regulated by GMP. Medicinal inspectors from the Norwegian Health Department performed initial inspections at all blood banks in the period 1994-98, and by now the majority have been GMP-certified. However, the Department has not given priority to regular control/ insepction of GMP-certified blood banks. This is particularly serious because the blood banks lack experience with the quality control procedures and responsibility requirements inherent in GMP.
Question 3
We hope that the National Institute of Health together with a new Transfusion Council will introduce quality assurance systems for blood banks.
Question 4
We have no requirements for accreditation of transfusion laboratories/centres.
Question 5
None of the Norwegian transfusion laboratories/centres are accredited today. However, several of the larger transfusion laboratories have recently started preparations for ISO 9000 and/or ISO/IEC 17025 accreditation. At Rikshospitalet we are in the state of having transplantation immunology accredited by EFI and the haematopoietic stem cell work by EBMT and ISHAGE. 
Olof Åkerblom Lisbeth Messeter

Question 1
The obligatory form of quality assurance is based on GMP and controls the preparation of blood components to be used as starting material for the manufacturing of medicinal products. The Swedish Medical Product Agency (MPA) has issued the appropriate provisions.
A voluntary form of quality assurance is based on EN 45001 (ISO 17025) and is applied to laboratory testing, methods for the preparation of blood components, and methods for compatibility testing and the issuing of blood components for transfusion.
The Swedish National Board of Health and Welfare (NBHW) has issued directives and recommendations for the activities at the blood centres. The NBHW strongly encourages all centres to implement quality assurance in their activities, but does not prescribe how this should be done.
The Guide to the preparation, use and quality assurance of blood components (Council of Europe) and the Handbook for Blood Centres (Swedish Society for Transfusion Medicine) are used as guidelines in all blood centres.
Question 2
Inspectors from the MPA inspect the blood centres every second year. Based on their reports (and after acceptance of corrections undertaken by the blood centres) the MPA gives the blood centre a licence, authority accreditation, to produce blood components (plasma) for the manufacturing of medicinal products.
The manufacturer receiving blood components as starting material for production of medicinal products has to inspect the blood centres regularly with regard to compliance to GMP.
Based on yearly inspections, the Swedish Board for Accreditation and Conformity Assessment (SWEDAC) may declare the blood centre to be accredited as a testing laboratory according to EN 45001. For blood centres, this is a voluntary procedure.
Question 3
Although there are two quality assurance systems for blood centres in our country, we have started discussions on creating a new Swedish 'Quality System for Blood Services', based on GMP, the new ISO 17025 (replacing the EN 45001), and including relevant elements from the new ISO 9001.
Question 4
In order to issue blood products (plasma) to be used as starting material for the manufacturing of medicinal products, the blood centre must have a licence from the MPA. The MPA can withdraw a licence in case of non-compliance to GMP. Without a licence, plasma from the blood centre may not be used for the manufacturing of medicinal products.
If the quality of performance in a blood centre does not comply with EN 45001, International Forum SWEDAC will not give or will withdraw the accreditation certificate. Since the accreditation is voluntary, the blood centre can still serve hospitals without accreditation (however, this means 'loss of face' and is therefore avoided at all costs).
Question 5
All of the 90 plus blood centres and blood and plasma collection sites in Sweden have received a licence from the MPA, allowing them to issue recovered and source plasma to be used as starting material for the manufacturing of medicinal products. The MPA inspections started in 1994 and licensing in 1995.
SWEDAC started in 1995 to accredit blood centres according to the EN 45001. Today, 28 blood centres have applied for, and received, such accreditation. 
V. James
Question 1
The Quality systems in the UK are based on ISO 9000; the principles of EN 45001 are incorporated into the Quality systems. GMP is compulsory.
The United Kingdom Blood Transfusion Services/National Institute of Biological Standards and Control: Guidelines for the Blood Transfusion Services in the United Kingdom (the Red Book) are compatible with the Council of Europe Guide and also appropriate EU Directives.
Question 2
There are several layers of systematic control with internal (individual Transfusion Centre based) and external quality audits.
The Medicines Control Agency (MCA) is responsible for licensing Transfusion Centres for the production of components and Fractionation Centres for the production of plasma derivatives.
Clinical Pathology Accreditation (CPA) is responsible for accrediting the diagnostic laboratory work at the Transfusion Centres.
New bodies have recently been created by the UK Government which will all have a role to play in the quality systems: National Institute of Clinical Excellence (NICE) and Commission for Health Improvement (CHI) in England and similar bodies in Scotland. A new concept called 'Clinical Governance' has been introduced and Chief Executives of Statutory Bodies are responsible for ensuring the quality of all work, including clinical work, carried out in their organisations.
Question 3
Not applicable.
Question 4
All Blood Transfusion Centres in the UK have to be licensed by MCA for the production of blood components. This is mandatory.
Accreditation by CPA for the diagnostic laboratories is still voluntary, but under the new systems of clinical governance may become mandatory.
MCA and CPA are responsible for granting or refusing licenses or accreditation, respectively.
If the MCA refuses to issue a license then the Centre cannot produce or issue any blood components, if the CPA refuses accreditation then the Centre will continue to function carrying out the diagnostic work but hospitals might soon stop referring samples.
Question 5
All Transfusion Centres in the UK have been licensed (mandatory) by the MCA since 1991.
Most diagnostic laboratories in centres have CPA accreditation since approximately 1990. Dr 
Martin Bruce
Question 1
In the UK, manufacturing and provision of blood components are undertaken at Blood Centres (BCs) and is considered a pharmaceutical manufacturing activity. These activities are regulated and licensed by the UK Medicines Control Agency (MCA). Therefore, it follows there is an obligatory requirement for a formal quality assurance system. From the regulatory perspective, this is based on GMP [1, 2] . Additionally, the UK Blood Services also comply with Guidelines for the Blood Transfusion Services in the UK [3] . This is a best practice guide that is based on the combined principles of GMP and ISO 9000 and takes account of the Council of Europe guidance in this area [4] .
It is generally accepted that the term 'blood banking' refers specifically to the provision of such services as pretransfusion testing, supply of blood for patients and antenatal/investigative serology, i.e. it is the provision of a clinical laboratory service for patients.
Currently there is no legislation governing quality standards in blood banking (or other pathology discipline) in the UK. However, blood banks are required to participate in National (UK) External Quality Assurance proficiency testing exercises for blood group serology.
A voluntary accreditation scheme for UK pathology laboratories has been established [5] and is contributing to a significant raising of standards. This scheme is not based on any established quality system but requires compliance with a number of defined standards that embrace the general principles of good and safe laboratory management and service provision.
Question 2
Blood component manufacturing quality systems are controlled at various levels, i.e.:
-by MCA regulatory inspections which, as a minimum, take place every two years or whenever there has been a significant change or problem; -the Scottish National Blood Transfusion Service (SNBTS) has a Quality Directorate which plays a lead role in monitoring performance (e.g. through audit, review of performance vs. key performance indicators and incident reporting); controlling change (e.g. SOPs, validation and implementation plans, recall) and promoting continuous improvement (e.g. through target setting; corrective/preventative action; sharing best practice); -all staff have a responsibility to control the quality of their own work.
The SNBTS cross-matches around half of the blood that is used in Scotland, therefore, the quality system elements listed above apply equally to blood banking in SNBTS (although at present these principles are less well established in the blood bank environment).
For other hospital blood banks, there is no independent Quality Department/Personnel. In these establishments, the extent and control of the quality system is largely based on the standards established by Clinical Pathology Accreditation UK Ltd (CPA).
In the past year, the UK Departments of Health have issued an instruction [6] notably to hospital Chief Executives, Medical Directors etc. drawing their attention to the importance of safe blood transfusion practice. Amongst the recommendations made was a requirement to establish Hospital Transfusion Committees. This, of itself, has brought an increased level of control. Further control and improvement are envisioned as the philosophy of Clinical Governance is implemented into the routine working of hospitals.
Question 3
The quality system requirements in Scotland have been described in some detail in responses 1 and 2.
Significant change is not envisaged in the near future.
Question 4
As has been described, blood component manufacture in the UK is regulated by the MCA. BCs submit and maintain a license application and site master file. The MCA Inspector will consider the contents of these documents and his findings at one or more audits when determining whether a license should be awarded.
The BC normally will be given a period of time to correct non-conformances identified at audit, the more serious the problem/s, the shorter the time given to effect corrective action.
Withdrawal of a license would be pursued only if the problems identified could not be resolved within an agreed time scale and/or the MCA considered there was a significant risk to patient safety.
With regard to Blood Banking, as has been mentioned, there is a voluntary system of accreditation. To date, the strongest indication that this will become a prerequisite for service provision appeared in a 1995 Department of Health (England and Wales) report [7] . This recommended that purchasers of pathology services use 'accredited' laboratories, but fell short of defining which system of accreditation should be used (e.g. ISO 9000; The King's Fund; Chartermark; CPA, etc.).
Most pathology services in the UK would acknowledge that CPA offers the most appropriate scheme. However, as participation in the scheme presently is voluntary, failure to secure accreditation does not result in withdrawal of the right to provide the service. That said, it is hoped that such a position would result in a redoubling of that establishment's efforts to correct the problems identified and secure accreditation.
Question 5
In the UK, the NHS and Community Care Act (1990) resulted in the removal of 'Crown Immunity' on 31 March 1991. For Blood Transfusion Services, this meant their manufacturing activities would be governed by the same rules which applied to the broader pharmaceutical industry. BCs were given 5 years to obtain a license from MCA. This was achieved and all Centres continue to be licensed. 
References
Question 2
The IMB grants the IBTS its Manufacturing Licence which covers the collection and processing of whole human blood and human plasma for use in the manufacture of medicinal products. The IMB also grants a Wholesaler's Licence in respect of the distribution of medicinal preparations. There are twice-yearly inspections to the above standards.
Question 4
Accreditation is not required, but it is an aspiration to seek accreditation from relevant bodies: CPA for Diagnostic Laboratories and European Federation for Immunogenetics (EFI) accreditation for the National Tissue Typing Reference Laboratory.
Question 5
The IBTS has two transfusion centres; the National Blood Centre is located in Dublin and the second centre is in Cork. Both centres are inspected to cGMP and licensed by the IMB. In addition, ISO 9000 accreditation and CPA have been granted to the regional blood centre.
Failure to maintain the required standard by the IMB would lead to not being able to export plasma for blood derivative manufacture. The consequences in terms of public/political disapproval would be very severe. However, the transfusion service is the sole supplier of allogeneic labile blood components, and as such would continue in this capacity pending renewal of licence. ISO 9000 and CPA accreditation are voluntary. Other activities that require an accreditation framework in the future are tissue banking and tissue typing. 
D. Schönitzer
Question 1
In Austria the ISO 9000 series for quality assurance is voluntary. GMP is obligatory for facilities producing blood products (Arzneimittelgesetz).
Since January 1st, 1999, the blood safety law (Blutsicherheitsgesetz) has been in action, which regulates in detail donor selection and blood donation. The law is mainly based on the Recommendation No. R (95) 15 on the preparation, use and quality assurance of blood components.
Question 2
Systematic control of ISO 9000 norms is performed by organisations like ÖQS, TÜV, DNV, Süd Cert and others.
GMP is controlled by the Federal Ministry for Labour, Health and Social Affairs and by Public-health officers under supervision of the government.
Question 3
Question 4
Obviously, there is no clear-cut distinction between certification and accreditation. However, GMP certification is required by the Federal Ministry for Labour, Health and Social Affairs. This body is responsible for granting or refusing certification. If certification is refused, a certain period of time will be given for corrective measures. If correction cannot be achieved, the laboratory or centre has to be closed (so far, this has never been the case). If the laboratory of a transfusion service performs tissue typing, EFI accreditation is required, if services are to be considerd acceptable within the framework of Eurotransplant.
Question 5
Transfusion centres with ISO 9000 certificate:
1995 
W.R. Mayr Gabriela Henn
Question 1
In Austria both systems of quality assurance are installed: an obligatory one, based on the Law on Blood Safety (Blutsicherheitsgesetz), corresponding to GMP and GLP which is under the surveillance of the Ministry of Health, and a voluntary one, which is based on ISO 9001 at our blood donation center. Our center is also interested in accreditation following EN 45001 for some activities. The ISO 9001 certification and the EN 45001 accreditation, however, are voluntary.
Question 2
The body responsible for systematic control of the obligatory part of the quality system in our country is, as mentioned above, the national health authority (Ministry of Health). For the voluntary part, certification is done by accredited companies; concerning the accreditation, we have to contact the Ministry of Economic Affairs or 'Notified Bodies' (e.g. TÜV) within the European Union.
Question 3
Question 4
In the near future, accreditation will only be required for laboratories performing tests on in vitro diagnostics for bulk release in the European Union. In general, Austria's as well as the European Union's philosophy tends to promote accreditation in the future.
Question 5
The 
Petra L'Herminez
Question 1
The executive board of Sanquin (the Dutch foundation for blood supply) has voluntarily decided that every division of Sanquin has to fulfill the requirements of GMP, ISO 9001 (2000) and -finally -EFQM. The implementation of these quality systems will be performed stepwise. Total implementation time is estimated to be at least 5 years (depending on the division).
Question 2
The Dutch Inspectorate of Health performs GMP inspections in the blood bank divisions on a 2-yearly basis. STERLAB accreditation is inspected by the 'Raad voor Accreditatie'.
Within Sanquin, an internal inspection systemis is in place for the blood bank divisions. This system is being enlarged to cover all parts of Sanquin.
Question 3
See above.
Question 4
No, the accreditation is not required or advocated by others than Sanquin self. 
Fulvio Mozzi Paolo Rebulla Girolamo Sirchia
Question 1
Health care structures willing to supply health services in Italy must pass two different steps: (a) authorization and (b) accreditation [1] . The first is based on the compliance to structural technologic and organizational requirements fixed by the national law [2] (only for health structures with in-patients) and regional regulations. Authorization is granted by the regional administrations and allows public or private health structures to supply health services, but not on behalf of the Na-
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Collection and production of blood components Laboratory control of blood donors In several States (e.g. Baden-Württemberg).
International Forum tional Health Service (NHS). To do this, accreditation is required, which is granted by the regional administrations following the assessment of the compliance to additional structural, technologic and organizational requirements, specific for each health-care area. These 'additional requirements' have been established by each regional administration for its own territory. They include, as in the case of the region Lombardia [3, 4] , in a more detailed way than the national law, the implementation and the regular application, in each structure, of a Quality Assurance System based and certified on the ISO 9000 series. Following the institutional accreditation, health structures become potential suppliers of health services on behalf of the NHS.
The National Blood Transfusion Service is regulated by a particular legislation [5] [6] [7] , which defines most of the product and service standards, but does not require the accreditation for the blood banks. Only the new national and regional laws concerning blood transfusion, now under discussion [8, 9] , will include the accreditation principle and define the requirements and the authorities for the accreditation, harmonizing the transfusion service with the NHS regulations.
In the meantime, many blood banks have started the implementation of their quality assurance systems based on the ISO 9000 series [10, 11] . In the last few years, the Società Italiana di Medicina Trasfusionale ed Immunoematologia (SIMTI) strongly promoted and supported this activity, also with the cooperation of the Italian National Institute of Health (Istituto Superiore di Sanità, ISS) through specific training courses and/or consultancy.
At present, several blood banks have in place a running quality assurance system certified on the ISO 9000 standards.
Question 2
The ISO 9000 certification process usually includes an initial comprehensive external audit, followed by a 3-year surveillance period during which external audits are performed every 6 months. Audits are performed by independent organizations, which have to be accredited by the respective national bodies (Sincert in Italy). The national accrediting bodies, as well as the certification bodies, have to comply with common international standards. This allows the international mutual recognition of the certification procedures.
Question 3
See answer to question 1.
Question 4
As mentioned before, accreditation is not yet mandatory for blood transfusion laboratories/centres, as stated in the answer to question 1, but it will with the new law. The Regional Administrations, directly or through independent bodies, will assess the compliance with the accreditation requirements, in view of granting or refusing accreditation. The initial assessments will be followed by regular surveillance.
In cases in which accreditation is refused, the organization will not be allowed to supply products and/or services on behalf of the NHS [3] and, consequently, to be paid.
Question 5
The quality system of the Centro Trasfusionale e di Immunologia dei Trapianti, based on the EN ISO 9002 : 1994 standard, was the first system to be awarded a certificate of approval in Italy (18th July, 1997).
Other Italian blood transfusion centres have been certified since. We expect that we and others will undergo accreditation in the next few months or years, according to prescriptions of the forthcoming blood transfusion law. 
F. Carbonell-Uberos
Question 1
In Spain there is a voluntary program for quality assurance of blood establishments based mainly on the Council of Europe Guide. This guide has been translated into Spanish by the Ministry of Health as the reference book. Several centres have been certified by ISO 9000 series and others are in preparation to meet these requirements.
Question 2
Licensing of blood establishments and mandatory inspections are the responsibility of regional health authorities. Voluntary accreditation is based on the program codeveloped by the AEHH (Spanish Association of Haematology and Haemotherapy) and the SETS (Spanish Society of Blood Transfusion). There is a Committee of Accreditation in Transfusion (CAT), formed by members of both societies, which is in charge of publishing the standards in transfusion, defining the areas of accreditation and the rules for the inspections of blood establishments.
Question 4
Accreditation of blood transfusion establishments is advocated by the two professional societies previously mentioned. The CAT is responsible for giving or not accreditation which is valid for 3 years. After this time, one needs to ask for a reaccreditation. The centre needs to be accredited in order to receive post-graduate doctors to specialise in haematology and transfusion medicine.
Question 5
Our centre and most of the blood transfusion centres and hospital-based transfusion services are accredited. The voluntary system of accreditation in Spain has started in 1975 and has been implemented progressively.
György Medgyesi
Before answering the specific questions, it might be appropriate to give some general information about the Hungarian Blood Transfusion Service. The law on health care adopted by the Hungarian parliament in 1997 declared the provision of blood and blood derivatives to be a governmental responsibility. According to this decision, blood transfusion centres have been organised into a National Blood Transfusion Service. At present the Service consists of six regional and 22 local centres co-ordinated and supervised by the Headquarters.
Question 1
The law on health care (law CLIV of 1997) mandates the application of quality assurance on health services. In accordance with this law, the Decree of the Hungarian Minister of Health (decree 43/1999, EuM) states that the Hungarian National Blood Transfusion Service operates a quality assurance system to control:
-the quality of the materials and reagents used in blood banking activity, -the adherence to professional guidelines and regulations, and -the fulfilment of requirements concerning personnel and equipment.
The quality assurance system adopted is based on GMP and the Council of Europe 'Guide to the Preparation, Use and Quality Assurance of Blood Components'.
Question 2
The Headquarters of the National Blood Transfusion Service regularly supervises the quality system within the blood transfusion centres.
Question 4
Accreditation of blood transfusion centres by bodies beyond the Headquarters of the National Blood Transfusion Service is currently under consideration at governmental level. 
M. Písačka
Question 1
In the Czech Republic there is an obligatory system of quality assurance, based on GMP and GLP. The national GMP and GLP regulations are based on Council of Europe Recommendation No. R (95)15 and its Appendix: 'Guide to the Preparation, Use and Quality Assurance of Blood Components'.
Question 2
The responsible body for the quality control of blood component production in the Czech Republic is the State Drug Control Institute (SUKL). Inspectors of SUKL control all procedures of transfusion production and fulfilment of GMP and GLP requirements is necessary for the accreditation (= state registration) of all transfusion centres. The external quality assurance system is based on proficiency testing. The immunohematology part is organized by the National Reference Laboratory for Immunohematology, which is part of the Institute of Hematology and Blood Transfusion. The proficiency test samples are distributed four times a year. The participants provide their results of ABO/RhD typing, further red cell antigens phenotyping, direct Coombs, antibody screening and identification (the extent of testing depends on the diagnostic range of each participant laboratory).
Further transfusion-related proficiency testing systems are organized by the respective National Reference Laboratories (NRL for HIV, hepatitis, syphilis, hematology, biochemistry), which are independent of the transfusion service.
Question 3
Question 4
The accreditation of blood transfusion laboratories involved in blood component preparation (transfusion centres) is part of the licensing process by SUKL. Refusal of accreditation should lead to cessation of blood component preparation by the respective centre.
The accreditation of other blood transfusion laboratories (blood banks -pretransfusion testing) is not required by national legislation, but the registration by state authorities and participation in the external quality assurance system is obligatory.
Question 5
67 transfusion centres are accredited by now (registered by the Ministry of Health, in cooperation with SUKL), but the accreditation of each centre will be re-evaluated (only by SUKL) in the near future -following the process of harmonisation of national legislation with the European Union. Dr 
M. Letowska
There are 21 Regional Centers for Transfusion Medicine (RCTM) in Poland, 16 of which are located in main cities. Each RCTM has its local blood bank (6-32) in smaller towns of the region. Within the scope of activity of each local blood bank lies: qualification of donors, blood collection and distribution of blood components. 95% of the local blood banks also deal with blood component preparation. This activity is supervised by the National Center for Transfusion Medicine (NCTM) with its seat in Warsaw.
Question 1
Polish RCTMs are obliged to adhere to the quality assurance system organized according to the regulations prepared and issued by the NCTM. This system of regulations is mainly based on the regulations of the Council of Europe as issued in 'Guide to the Preparation and Quality Assurance of Blood Components' as well as on the principle of GMP and GLP.
Question 2
Quality assurance is supervised by the Quality Assurance Divisions of each RCTM. They bear responsibility for SOP, systematic audits of all divisions and local blood banks, staff training and current quality control of blood components. Every month, employees of the Quality Assurance Division analyze quality control documents sent in by the local blood banks and at least once a year audits of each local blood bank are organized. All RCTMs are supervised by the NCTM. At least once in 2 years every RCTM plus one selected local blood bank International Forum are audited by representatives of the NCTM. During such inspections, attention is paid mainly to the functioning of Quality Assurance Divisions.
Question 3
Questions 4 and 5
In Poland the public blood transfusion service constitutes an integral part of the public health service. The Polish blood transfusion service functions according to the regulations introduced with the governmental law of January 1st 1999. According to this law, blood may be collected in public blood transfusion centers only. All RCTMs are funded by the Ministry of Health while their functioning is supervised by the NCTM. Such supervision is conducted by way of regular audits and inspections of the regions. If serious faults in the activity of the regional unit are found during inspections, the Ministry of Health may be approached for a change of director or the closure of the blood bank. 
Mary Gustafson
Question 1
The Food and Drug Administration's (FDA) current good manufacturing practices (cGMP) regulations for blood and blood components [in Title 21, Code of Federal Regulations, Part 606 (21 CFR 606)] and drugs (21 CFR 211) apply. These are mandatory requirements for blood establishments. FDA's Center for Biologics Evaluation and Research (CBER) prepared a guideline for industry to assist blood establishments in conducting quality programs consistent with the applicable regulations. The guideline is 'Guideline for Quality Assurance in Blood Establishments', July 11, 1995 (Docket No. 91N-0450) . This guideline is available on the world wide web (http://www.fda.gov/cber/ gdlns/gde_qa).
In addition, there are several voluntary quality programs, including the AABB's quality system and ISO 9000.
Question 2
In the US, the FDA is respnsible for the federal regulation of blood establishments, including quality requirements. Voluntary organizations that have accreditation programs, such as the AABB, also oversee quality in their members' facilities.
Question 3
Question 4
In the US, blood establishments that transfer blood and blood components from one US state to another must be licensed by the FDA. All blood establishments, whether they share blood or not, are inspected by the FDA against cGMP standards. There are federal civil court penalties for failure to adhere to cGMP. In addition, voluntary organizations, such as the AABB, have accreditation programs for their members. 
Peter Ganz
Before responding specifically to your questions, let me preface our answers by emphasizing that these answers are offered as those of the national regulatory authority. In Canada this is the federal government, specifically, the Therapeutic Products Programme of the Health Protection Branch which is responsible for regulation of the blood system. Operators of the blood system, Canadian Blood Services (CBS) and Héma-Québec (HQ) should be requested to provide answers for some questions for which they have authority, i.e. question 2 and/or question 4.
Question 1
Yes there is an organized form of quality assurance. The quality options in place follow GMP requirements defined in legislation (Division 2 of Canada's Food and Drugs Act and Regulations). Blood is regulated as a drug in Canada and parts of this federal legislation require that quality systems be in place within the Canadian Blood System. The Drugs Directorate Guidelines for blood and blood component manufacturing are in place and define the requirements for operations. Also, New National Blood Safety Standards have been drafted and will be referenced in legislation in the near future.
Question 2
Yes there is a system control of quality systems. Canada's blood system operators (CBS and HQ) are responsible for having these systems in place and the federal government (Therapeutic Products Programme) is responsible for ensuring that it meets regulatory standards.
Question 3
Not applicable given response to question 2.
Question 4
Blood transfusion centres in Canada are licensed by the federal government and thus do not need to be accredited since existing federal licensing represents the ultimate degree of regulatory oversight. Some transfusion centres are, however, accredited by AABB or Canadian Society of Transfusion Medicine, but these are voluntary.
Question 5
Refer to answer in question 4. It is necessary to contact CBS and HQ to seek out information about their respective accreditation status. 
J. Wesley Rees
Question 2
Our Regulator, the Bureau of Biologics and Radiopharmaceuticals (BBR) is responsible for ensuring that all firms engaged in the collection of blood and the manufacture of blood components have a quality system that satisfies minimum requirements. The BBR ensures the systematic control of the quality system through routine annual inspections.
In addition, each firm is responsible for deciding the quality standards (in excess of the minimum) it wishes to achieve and for ensuring that its quality system produces this level of quality. CBS is currently working with Canada's National Quality Institute to establish a quality system that is based on the criteria of the Canadian Framework of Business Excellence.
Question 4
Transfusion Centres, such as those operated by CBS and Héma-Québec, that collect, test, manufacture and distribute blood and blood components are required to obtain a licence from the government of Canada. (Dr. Ganz heads the government agency responsible for this licensing process.) The requirements for licensing are defined in the Food and Drugs Act (Canada) and in Regulations and Guidelines published pursuant thereto. If 'accreditation' is refused or revoked, a centre may not legally operate. Violations of the legal requirements may be prosecuted in criminal court.
Currently, accreditation of hospital blood banks (which store blood and blood components and manage their actual transfusion to patients) is not required on a national basis. The federal government has been considering a national program for several years. Provincial governments, often in concert with the provincial college of physicians, maintain personal professional accreditation programs.
Question 5
The Canadian Red Cross Society, which previously operated Canada's blood system, was 'accredited' (i.e. licensed by the federal government) in September 1989, the point at which the requirement became effective. Canadian Blood Services (and Héma-Québec) have maintained this status since taking over the role of operator in September 1998. Dr 
Francine Décary
Question 2
The Regulatory Affairs Department is responsible for the systematic control or our quality system. Quality Assurance (including Quality control), Compliance and Licensing, Training and Audits are all sections under Regulatory Affairs. Quality assurance is responsible for non-conformance management, our material acceptance and the quality control of blood products. Compliance and licensing is responsible for submissions to the Regulatory Agency including SOPs manufacturing changes, error/accident reports and adverse events reports. The Training section is responsible for the trainer programme, GMP training programme and accessing other training programme. The Audits section is responsible for internal audit programme, supplier audits and facilitation of regulatory agency audits.
Question 4
Yes we are licensed by the Therapeutic Product Programme of Health Canada according to GMP.
The Bureau of Biologics and radiopharmaceutical is responsible for granting licensing. If ever licensing is refused, we would have to cease operations. 
Silvano Wendel Paulo T. Rodrigues Almeida
Question 1
In Brazil, the Brazilian Ministry of Health, under the National Vigilance Agency, is responsible for enacting all guidelines which have to be followed by all Blood Services in the national territory. Currently, Act 1376 [1] is the one in practice in Brazil and it is mandatory that all services involved with blood transfusion activity must have a systematic programme of quality concerning all aspects of collection, processing and transfusion of blood products.
The Brazilian Act 1376 does not state with precision how this programme should be performed, nor which organisation is responsible to evaluate the performance of each Brazilian Blood Service, however, there are two organisations currently involved in defining programmes for that: the Brazilian Association of Blood Banks (ABBS) and the Brazilian Society of Haematology and Haemotherapy (SBHH). The first organisation, which is responsible for evaluating only the private sector (currently with 46 members, collecting approximately 600,000 donations/ year) launched a mandatory programme in June 2000. On the other hand, for the SBHH programme, this is a voluntary activity from the services that would like to be continuously evaluated. Both programmes (ABBS and SBHH) are based on different international organisations (AABB, Council of Europe, ISO 9000 series, GMP, GLP, FDA) and the Brazilian Acts 1376 and 121 [2] . In addition to that, the Brazilian Ministry of Health, launched in 1998 the National project 'Blood, 100% of Quality Assurance in all steps', will be responsible for assuring quality to all public Blood Services (with approximately 1,400,000 collections/year) by the year 2003.
Question 2
Since either the ABBS and SBHH programmes were launched in 2000, and the Brazilian Ministry of Health programme has not been put in practice yet, there are some speculations of which organisation (a single, multiple?) will definitely be responsible for the systematic control. The ABBS programme has taken the own responsibility of controlling its mandatory quality assurance programme, under the responsibility of the ABBS Quality Department; a group enrolling the staff from all associates is now undergoing a training programme, and it is expected that all aspects of control and accreditation will be fully implemented by June 2001. On the other hand, the SBHH programme will be under the responsibility of the National Accreditation Organisation (ONA), an external organisation with experience in the field of Hospital Accreditation, though this is going to be the first project in the Blood Transfusion field.
Question 3
Not applicable, since it has already been answered in questions 1 and 2.
Question 4
A Blood Service license in Brazil (either public or private) is granted by the Brazilian Ministry of Health, through each State Sanitary Secretary. Only certain aspects are required, and granting is allowed once the Service fulfils the requirements of Act 1376, although a specific accreditation programme is not necessary as far as quality assurance is concerned. Thus, the first step of any Blood Service to have a license is to be inspected by the Local State Sanitary Agency. Without it, International Forum regardless of any accreditation programme, no service is allowed to be operative. However, if these services, once initially licensed, later submit to one of the aforementioned accreditation programmes (ABBS or SBHH) and are refused, there is no legal power from such organisations to revoke the already established license to supply blood products to the public, although in the ABBS programme, if the accreditation is refused, the service will be excluded as an ABBS member.
Question 5
Since the national accreditation programmes are in the early phase, there are no services which have already been accredited (at least one year is expected until the first accreditations are fully implemented). On the other hand, there are some Brazilian services that have submitted to the AABB or ISO 9002 accreditation, the first one in late 1998.
